George Pavlov bought $441k of MPLT
director at MapLight Therapeutics, Inc.. 25,000 shares at an average of $17.65, traded Feb 18, 2026, filed Feb 20, 2026.
Score components
- +15RoleDirector
- +17Trade size$441k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context18% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.8%, 3m +60.8%, 6m -37.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470798-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | POpen-market purchase Voting Common Stock | +10,658 | $17.48 | $186k | 10,658 | Feb 20, 2026 |
| Feb 19, 2026 | POpen-market purchase Voting Common Stock | +4,422 | $17.57 | $78k | 15,080 | Feb 20, 2026 |
| Feb 20, 2026 | POpen-market purchase Voting Common Stock | +9,920 | $17.86 | $177k | 25,000 | Feb 20, 2026 |
Related signals
Other insiders at MapLight Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $193k 16,509 shares | -11% | |
| 45Moderate | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $3.2M 118,235 shares | -8% | |
| 21Weak | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $127k 4,438 shares | -1% | |
| 26Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $419k 13,917 shares | -8% | |
| 45Moderate | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $1.9M 68,491 shares | -4% | |
| 10Weak | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $20k 721 shares | -0% | |
| 40Moderate | MapLight Therapeutics, Inc. | Erin Pennock Foff Chief Medical Officer | $1.4M 50,280 shares | -13% | |
| 26Weak | MapLight Therapeutics, Inc. | Kristopher Hanson General Counsel | $388k 13,917 shares | -7% | |
| 45Moderate | MapLight Therapeutics, Inc. | Christopher A. Kroeger Chief Executive Officer | $1.4M 49,744 shares | -3% | |
| 40Moderate | MapLight Therapeutics, Inc. | James Woodruff Lillie Chief Scientific Officer | $1.5M 51,707 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.